Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Hemochromatosis
• MONDO ID: (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Hemochromatosis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Hemochromatosis (Hereditary Hemochromatosis; HH) — Comprehensive Disease Characteristics Report (2024–2026 evidence emphasis)

Executive summary

Hemochromatosis refers to a group of inherited iron-overload disorders in which insufficient hepcidin activity (or resistance to hepcidin) causes inappropriately increased intestinal iron absorption, elevated transferrin saturation (TSAT), generation of toxic non–transferrin-bound iron, and progressive iron deposition in multiple organs. The most common form is HFE-related hereditary hemochromatosis (classically HFE p.Cys282Tyr (C282Y) homozygosity), which is common in Northern European ancestry but has variable/low clinical penetrance; non‑HFE forms are rarer but often more penetrant and may present earlier with severe complications. Standard care is iron removal by phlebotomy with guideline-based ferritin targets; new pharmacologic approaches aim to replace/augment hepcidin signaling or inhibit ferroportin, potentially reducing phlebotomy burden. (girelli2024diagnosisandmanagement pages 1-2, girelli2024diagnosisandmanagement pages 2-4, szczerbinska2024hemochromatosis—hownotto pages 8-10)

1. Disease information

1.1 Definition and overview

• Disease concept: HH is a genetic iron overload syndrome characterized by hepcidin insufficiency (or hepcidin resistance) with normal erythropoiesis, leading to iron hyperabsorption, increased TSAT (diagnostic hallmark), formation of non–transferrin-bound iron, and iron deposition in organs (liver, heart, endocrine glands, joints). (girelli2024diagnosisandmanagement pages 1-2)
• Authoritative definition (abstract quote): “The term hemochromatosis refers to a group of genetic disorders characterized by hepcidin insufficiency… iron hyperabsorption… increased transferrin saturation, the diagnostic hallmark of the disease.” (Girelli et al., Hematology 2024; published Dec 2024; https://doi.org/10.1182/hematology.2024000568) (girelli2024diagnosisandmanagement pages 1-2)

1.2 Key identifiers (availability in retrieved sources)

The tool-retrieved corpus for this run did not include OMIM/Orphanet/ICD-10/ICD-11/MeSH pages, so those identifiers cannot be cited from primary source documents here. - MONDO ID: not available from the citable evidence retrieved in this run.

1.3 Synonyms / alternative names

Common names used in contemporary literature include: - Hereditary hemochromatosis (HH), HFE-hemochromatosis (HFE-H), classic hemochromatosis, iron overload disease. (girelli2024diagnosisandmanagement pages 1-2, szczerbinska2024hemochromatosis—hownotto pages 1-2)

1.4 Evidence provenance

Evidence summarized here is derived from aggregated disease-level resources (peer-reviewed reviews/guideline syntheses) and large population cohorts (UK Biobank), plus clinical trial registry records; it is not derived from individual EHR case reports except where cohort outcomes were ascertained from routine care data linkages. (lucas2024hfegenotypeshaemochromatosis pages 4-5, NCT04202965 chunk 1)

2. Etiology

2.1 Primary causal factors

• Genetic:
• HFE-related HH most commonly due to HFE p.Cys282Tyr (C282Y) homozygosity. (girelli2024diagnosisandmanagement pages 1-2, szczerbinska2024hereditaryhemochromatosis–hownot pages 8-9)
• Non‑HFE HH includes defects in hepcidin synthesis/regulation (e.g., HJV, HAMP, TFR2) and hepcidin resistance (e.g., SLC40A1/ferroportin). (szczerbinska2024hemochromatosis—hownotto pages 8-10, girelli2024diagnosisandmanagement pages 2-4)
• Mechanistic: dysregulation of the hepcidin–ferroportin axis is central, leading to increased iron export into plasma and increased intestinal absorption. (girelli2024diagnosisandmanagement pages 1-2, szczerbinska2024hemochromatosis—hownotto pages 1-2)

2.2 Risk factors (genetic and environmental/lifestyle)

• Sex is a major modifier: HFE-H has “low penetrance, particularly in females.” (Girelli et al., Hematology 2024; Dec 2024; https://doi.org/10.1182/hematology.2024000568) (girelli2024diagnosisandmanagement pages 1-2)
• Lifestyle/metabolic cofactors modulate clinical expression; HFE-H can be considered “multifactorial” with “genetic and lifestyle cofactors (especially alcohol and dysmetabolic features)” influencing phenotypic expression. (girelli2024diagnosisandmanagement pages 1-2, girelli2024diagnosisandmanagement pages 2-4)

2.3 Protective factors

• A commonly cited physiologic protection in females is iron loss through menstruation/pregnancy; contemporary reviews emphasize lower penetrance in females, consistent with this biological mechanism. (girelli2024diagnosisandmanagement pages 1-2)

2.4 Gene–environment interactions

HFE-H is explicitly described as resembling a multifactorial condition because environmental and metabolic factors (e.g., alcohol, coexisting metabolic liver disease) interact with HFE genotype to determine penetrance and severity. (girelli2024diagnosisandmanagement pages 2-4)

3. Phenotypes (clinical features) and HPO mappings

3.1 Core phenotype spectrum (disease-level)

HH can cause multisystem iron deposition with manifestations in: - Liver: iron overload, fibrosis/cirrhosis, hepatocellular carcinoma (HCC) risk in advanced fibrosis/cirrhosis. (girelli2024diagnosisandmanagement pages 2-4, marcon2024tsaturatedinsightsclarifying pages 16-17) - Musculoskeletal: arthropathy and increased joint replacement incidence in p.C282Y homozygotes in community cohorts. (lucas2024hfegenotypeshaemochromatosis pages 4-5, lucas2024hfegenotypeshaemochromatosis pages 7-7) - Endocrine/metabolic: diabetes risk increased in male p.C282Y homozygotes in UK Biobank outcomes. (lucas2024hfegenotypeshaemochromatosis pages 6-7) - Neurologic (association signals): delirium/dementia/Parkinson’s disease associations reported in UK Biobank analyses (interpretation cautious due to multiple-testing). (lucas2024hfegenotypeshaemochromatosis pages 6-7)

3.2 Phenotype timing and progression

• Typical onset: adult-onset is typical for HFE-H; non-HFE forms can present earlier and more severely (e.g., juvenile forms). (girelli2024diagnosisandmanagement pages 1-2, szczerbinska2024hemochromatosis—hownotto pages 8-10)

3.3 Quantitative phenotype frequencies / statistics (UK Biobank; BMJ Open 2024)

From a large prospective cohort with outcomes to age 80: - Male p.C282Y homozygotes: cumulative incidence of diagnosed hemochromatosis ~56.4% by age 80, and higher all-cause mortality (HR 1.29; 95% CI 1.12–1.48) with cumulative death incidence 33.1% vs 25.4% in those without HFE variants. (Lucas et al., BMJ Open; published Mar 2024; https://doi.org/10.1136/bmjopen-2023-081926) (lucas2024hfegenotypeshaemochromatosis pages 4-5) - Women p.C282Y homozygotes: cumulative incidence of diagnosed hemochromatosis 40.5% by age 80. (lucas2024hfegenotypeshaemochromatosis pages 6-7) - Genotypes with low penetrance: p.C282Y/p.H63D and p.H63D+/+ showed low diagnosis cumulative incidences (~5.4% in men and ~2.7% in women for compound heterozygotes; ~1.9% for H63D homozygosity). (lucas2024hfegenotypeshaemochromatosis pages 7-7)

3.4 Suggested HPO terms (examples)

(These are ontology mapping suggestions for knowledge base normalization.) - Elevated transferrin saturation: HP:0012467 (Abnormal iron saturation) (map conceptually to TSAT elevation) (supported conceptually by TSAT as hallmark) (girelli2024diagnosisandmanagement pages 1-2) - Hyperferritinemia: HP:0003281 (supported by diagnostic role of ferritin) (girelli2024diagnosisandmanagement pages 2-4) - Hepatic iron overload: HP:0003280 (supported by MRI/LIC role and hepatic deposition) (szczerbinska2024hemochromatosis—hownotto pages 8-10) - Liver fibrosis/cirrhosis: HP:0001395 (supported by increased fibrosis/cirrhosis risk) (lucas2024hfegenotypeshaemochromatosis pages 6-7) - Diabetes mellitus: HP:0000819 (supported by increased diabetes incidence in male p.C282Y homozygotes) (lucas2024hfegenotypeshaemochromatosis pages 6-7) - Arthropathy / joint disease: HP:0002829 (supported by increased joint replacement risk) (lucas2024hfegenotypeshaemochromatosis pages 4-5) - Fatigue: HP:0012378 (supported by baseline fatigue signal in older male homozygotes) (lucas2024hfegenotypeshaemochromatosis pages 4-5)

3.5 Quality of life impact

Direct QoL instrument data (e.g., SF-36/EQ-5D) were not retrieved in the citable evidence set for this run; however, symptoms such as fatigue and joint disease are plausibly QoL-limiting, and fatigue associations were directly quantified in UK Biobank (baseline OR in older men). (lucas2024hfegenotypeshaemochromatosis pages 4-5)

4. Genetic / molecular information

4.1 Causal genes (major)

• HFE (type 1, classic), HJV, HAMP, TFR2, SLC40A1 (non-HFE forms including juvenile hemochromatosis and ferroportin disease spectrum). (girelli2024diagnosisandmanagement pages 1-2, szczerbinska2024hemochromatosis—hownotto pages 8-10, girelli2024diagnosisandmanagement pages 2-4)

4.2 Key pathogenic variants and genotype interpretation

• HFE-H is strongly linked to HFE p.Cys282Tyr (C282Y) homozygosity, which is common in Northern European ancestry but has variable clinical penetrance. (girelli2024diagnosisandmanagement pages 1-2)
• BIOIRON-aligned interpretation emphasizes C282Y homozygosity as the pathogenic HFE genotype for HFE-related HH, with substantial debate/variation in how other HFE genotypes should be managed. (marcon2024tsaturatedinsightsclarifying pages 1-2, marcon2024tsaturatedinsightsclarifying pages 16-17)

4.3 Modifier genetics (polygenic effects)

A recent UK Biobank analysis (preprint) suggests a polygenic score for TSAT modifies clinical penetrance among C282Y homozygotes, with higher genetically predicted TSAT increasing clinical outcome incidence; this requires peer-reviewed validation. (lucas2025geneticandlifestyle pages 12-15)

4.4 Functional consequences (current understanding)

Across HH types, the shared physiological consequence is inappropriately low hepcidin effect relative to body iron, leading to increased plasma iron and tissue deposition. (girelli2024diagnosisandmanagement pages 1-2, girelli2024diagnosisandmanagement pages 2-4)

4.5 Epigenetics / chromosomal abnormalities

No epigenetic or chromosomal-abnormality evidence specific to HH was retrieved in the citable set for this run.

5. Mechanism / pathophysiology

5.1 Causal chain (high-level)

1) Genetic defect (HFE or non-HFE hepcidin pathway genes) → 2) Hepcidin insufficiency or resistance → 3) Increased ferroportin-mediated iron export + increased intestinal iron absorption → 4) High TSAT and non–transferrin-bound iron formation → 5) Parenchymal iron deposition (liver, heart, endocrine glands, joints) → 6) Oxidative injury and organ dysfunction. (girelli2024diagnosisandmanagement pages 1-2, szczerbinska2024hemochromatosis—hownotto pages 1-2)

5.2 Pathways and processes (ontology suggestions)

• Key pathway: hepcidin–ferroportin axis / systemic iron homeostasis. (girelli2024diagnosisandmanagement pages 1-2)
• Suggested GO biological process terms:
• Iron ion homeostasis (GO:0055072)
• Cellular iron ion homeostasis (GO:0006879)
• Regulation of hepcidin production (conceptual mapping; hepcidin insufficiency is central) (girelli2024diagnosisandmanagement pages 1-2)
• Suggested cell types (Cell Ontology, CL) implicated by organ deposition and regulation discussions:
• Hepatocyte (CL:0000182) (hepcidin production context) (girelli2024diagnosisandmanagement pages 1-2)
• Macrophage / Kupffer cell (CL:0000235 / liver macrophage) (iron handling in liver; discussed as important in regulation frameworks) (girelli2024diagnosisandmanagement pages 2-4)
• Enterocyte (CL:0000584) (intestinal absorption) (szczerbinska2024hemochromatosis—hownotto pages 1-2)

5.3 Immune/inflammation involvement

While ferritin is noted to be nonspecific and increased in inflammatory states (confounding differential diagnosis), direct immune-pathogenesis evidence was not central in the retrieved set beyond this diagnostic confounding. (girelli2024diagnosisandmanagement pages 2-4)

5.4 Molecular profiling / omics

No transcriptomic/proteomic/metabolomic disease signatures were retrieved as citable evidence in this run.

6. Anatomical structures affected (UBERON suggestions)

• Liver (primary): UBERON:0002107 (hepatic iron loading; fibrosis/cirrhosis/HCC surveillance considerations). (girelli2024diagnosisandmanagement pages 2-4, lucas2024hfegenotypeshaemochromatosis pages 6-7)
• Heart: UBERON:0000948 (iron deposition cited as part of multisystem accumulation). (girelli2024diagnosisandmanagement pages 1-2)
• Endocrine glands/pancreas: UBERON:0001264 (pancreas; diabetes association) (girelli2024diagnosisandmanagement pages 1-2, lucas2024hfegenotypeshaemochromatosis pages 6-7)
• Joints/synovium: UBERON:0002206 (synovial joint) (girelli2024diagnosisandmanagement pages 1-2)

Subcellular (GO cellular component suggestions): lysosome (GO:0005764) and mitochondrion (GO:0005739) are plausible sites of iron-related oxidative injury, but specific subcellular localization evidence was not retrieved in the citable set.

7. Inheritance and population

7.1 Inheritance patterns

• HFE-H (type 1): typically autosomal recessive. (girelli2024diagnosisandmanagement pages 1-2)
• Non-HFE juvenile forms (HJV/HAMP/TFR2): autosomal recessive. (szczerbinska2024hemochromatosis—hownotto pages 8-10, girelli2024diagnosisandmanagement pages 2-4)
• Ferroportin-related (SLC40A1): often autosomal dominant with hepcidin resistance phenotypes described. (szczerbinska2024hemochromatosis—hownotto pages 8-10)

7.2 Population frequency and penetrance (recent synthesis)

• Prevalence of genetic risk genotype: HFE C282Y homozygosity is described as present in “nearly 1 in 200 people of Northern European descent.” (Girelli et al., Hematology 2024; Dec 2024; https://doi.org/10.1182/hematology.2024000568) (girelli2024diagnosisandmanagement pages 1-2)
• Clinical penetrance is variable/low: review syntheses emphasize variable penetrance and diagnostic complexity. (marcon2024tsaturatedinsightsclarifying pages 1-2, girelli2024diagnosisandmanagement pages 1-2)

8. Diagnostics

8.1 Core laboratory hallmarks

• TSAT is the “diagnostic hallmark” in HH definitions; thresholds around >45–50% are commonly used to trigger evaluation. (girelli2024diagnosisandmanagement pages 1-2, szczerbinska2024hemochromatosis—hownotto pages 8-10)
• Ferritin is used to quantify iron burden but is nonspecific and can be elevated in inflammation, cytolysis, or metabolic conditions. (girelli2024diagnosisandmanagement pages 2-4)

8.2 Guideline elements and algorithms (visual evidence from a 2024 guideline synthesis)

The Marcon et al. 2024 review provides comparative tables and an algorithm that summarize guideline differences for diagnosis and phlebotomy targets: - Table comparing diagnostic elements (TSAT/SF cutoffs) across guidelines and Table comparing treatment targets (including induction and maintenance serum ferritin goals). (marcon2024tsaturatedinsightsclarifying media 39ab28d3, marcon2024tsaturatedinsightsclarifying media 7ecf4a95) - Diagnostic/management algorithm (figure) for HFE-related HH and differential diagnosis approach to hyperferritinemia. (marcon2024tsaturatedinsightsclarifying media f71af5e5, marcon2024tsaturatedinsightsclarifying media 8a05bd9e)

8.3 Imaging and biopsy

• MRI is highlighted as a reference/essential technique for hepatic iron quantification and staging in contemporary practice; liver biopsy is described as rarely required in modern workups except selected cases. (marcon2024tsaturatedinsightsclarifying pages 16-17, szczerbinska2024hemochromatosis—hownotto pages 8-10)

8.4 Genetic testing strategy

• HFE accounts for the vast majority of hereditary cases; genetic testing is described as the “gold standard diagnostic test,” with initial biochemical screening by TSAT and ferritin. (nogueyra2024thegeneticdiagnostics pages 3-4)
• If C282Y is absent but iron overload is present, reviews recommend considering gene panels for non‑HFE etiologies after excluding common secondary causes (e.g., metabolic liver disease, alcohol-associated liver disease). (szczerbinska2024hemochromatosis—hownotto pages 8-10, szczerbinska2024hereditaryhemochromatosis–hownot pages 9-11)

8.5 Differential diagnosis (high level)

• Hyperferritinemia with normal TSAT is often not HH and may reflect metabolic/inflammatory etiologies; specialist evaluation is recommended in such patterns. (girelli2024diagnosisandmanagement pages 2-4)

9. Outcomes / prognosis

9.1 Prognosis with early treatment

• Reviews emphasize that contemporary HFE-H is “mostly diagnosed before organ damage and is easily treated by phlebotomy, with an excellent prognosis.” (Girelli et al., Hematology 2024; Dec 2024; https://doi.org/10.1182/hematology.2024000568) (girelli2024diagnosisandmanagement pages 1-2)

9.2 Morbidity and mortality statistics (UK Biobank)

• Male p.C282Y homozygotes showed increased all-cause mortality (HR 1.29; cumulative deaths 33.1% vs 25.4% by age 80) and increased liver/joint/other outcomes. (lucas2024hfegenotypeshaemochromatosis pages 4-5)
• These outcome signals were also seen among individuals undiagnosed at baseline, supporting under-recognition in routine care. (lucas2024hfegenotypeshaemochromatosis pages 4-5)

10. Treatment

10.1 Standard-of-care: phlebotomy (venesection)

• First-line therapy: repeated therapeutic phlebotomy (venesection), commonly ~450–500 mL per session. (marcon2024tsaturatedinsightsclarifying pages 16-17, szczerbinska2024hereditaryhemochromatosis–hownot pages 9-11)
• Example induction/maintenance targets from cited EASL-aligned summaries: ferritin targets often include <50 µg/L during induction and <100 µg/L during maintenance; TSAT is not necessarily a treatment target in some guidelines. (szczerbinska2024hereditaryhemochromatosis–hownot pages 9-11)
• A 2024 synthesis includes comparative guideline tables for phlebotomy targets (induction and maintenance) and a diagnostic/treatment algorithm. (marcon2024tsaturatedinsightsclarifying media 39ab28d3, marcon2024tsaturatedinsightsclarifying media 7ecf4a95, marcon2024tsaturatedinsightsclarifying media f71af5e5)

10.2 Blood donation as real-world implementation

After iron depletion, maintenance phlebotomy “can be usefully transformed into a blood donation program,” representing a practical implementation pathway in suitable health systems. (girelli2024diagnosisandmanagement pages 1-2)

10.3 Chelation therapy (selected indications)

Chelation is generally reserved for patients who cannot undergo phlebotomy or are refractory/intolerant, due to toxicity and limited evidence relative to phlebotomy. (nogueyra2024thegeneticdiagnostics pages 3-4, marcon2024tsaturatedinsightsclarifying pages 31-31)

10.4 Emerging / investigational therapies (2023–2026)

Hepcidin mimetic / hepcidin-pathway augmentation

• Rusfertide (PTG‑300): ClinicalTrials.gov describes a Phase 2, open-label, single-arm study in adults with HFE-related HH (NCT04202965), completed, with results first posted 2023‑06‑15. Primary endpoints included change in TSAT and serum iron to Week 24, and a key secondary endpoint was change in phlebotomy frequency over 24 weeks pre vs on treatment. (ClinicalTrials.gov; posted results 2023-06-15; https://clinicaltrials.gov/study/NCT04202965) (NCT04202965 chunk 1)

Ferroportin inhibition

• Vamifeport: A Phase 2 interventional trial record exists for HFE-related HH (NCT07332091, CSL Behring) with a record version date 2026‑04‑30 and multiple European sites listed as not yet recruiting in the extracted chunk; additional registry chunks are needed for endpoints/dosing. (ClinicalTrials.gov; https://clinicaltrials.gov/study/NCT07332091) (NCT07332091 chunk 4)

10.5 MAXO term suggestions

• Therapeutic phlebotomy / venesection: MAXO:0000449 (therapeutic phlebotomy; conceptual mapping)
• Iron chelation therapy: MAXO:0000755 (chelation therapy; conceptual mapping)
• Genetic counseling/cascade testing: MAXO:0000079 (genetic counseling; conceptual mapping)

11. Prevention

11.1 Secondary prevention: early detection and intervention

• The disease evolves over decades and is highly amenable to preventing complications via early recognition and venesection, motivating screening discussions. (delatycki2024populationscreeningfor pages 1-2, girelli2024diagnosisandmanagement pages 1-2)

11.2 Screening strategies (2024 expert analyses)

• Population screening (expert argument in favor): Delatycki & Allen (2024) argue HH is a strong candidate for population genetic screening because early intervention is simple and effective, and may expand the blood donor pool; they discuss genotype vs phenotype screening tradeoffs and conclude it is timely to reconsider genotype-based strategies focusing on C282Y. (Delatycki & Allen, Genes; Jul 2024; https://doi.org/10.3390/genes15080967) (delatycki2024populationscreeningfor pages 1-2, delatycki2024populationscreeningfor pages 4-5, delatycki2024populationscreeningfor pages 5-6)
• Caution/targeted screening: Another 2024 review emphasizes underdiagnosis but suggests targeted screening (e.g., higher-risk ancestry/sex subgroups) rather than universal screening, partly due to lower-than-expected penetrance. (szczerbinska2024hemochromatosis—hownotto pages 13-14)

11.3 Cascade screening and counseling

• Family screening for first-degree relatives is repeatedly recommended/implicit in diagnostic frameworks because of the inherited nature and actionable intervention. (szczerbinska2024hereditaryhemochromatosis–hownot pages 9-11)

12. Other species / natural disease

No veterinary/natural disease evidence (OMIA/VetCompass) was retrieved in the citable set for this run.

13. Model organisms

No model organism-specific primary studies were retrieved in the citable set for this run.

14. Structured summary artifact (genes/types)

The following table summarizes major HH types, genes, inheritance, and mechanistic class.

Table: This table summarizes the major hereditary hemochromatosis subtypes, their causal genes, inheritance patterns, core pathophysiology, and typical clinical presentation. It is useful as a compact reference for distinguishing classic HFE-related disease from rarer, often more penetrant non-HFE forms.

15. Notes on evidence gaps in this run

• Ontology identifiers (OMIM, Orphanet, ICD-10/11, MeSH, MONDO) were not retrievable as citable sources in this run; a follow-up retrieval targeting those databases would be required to populate identifiers with citations.
• Detailed omics, epigenetic findings, animal models, and QoL instrument-based outcomes were not retrieved in the citable evidence set for this run.

Key recent sources (with URLs and publication dates)

• Girelli D, Marchi G, Busti F. Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation. Hematology. Dec 2024. https://doi.org/10.1182/hematology.2024000568 (girelli2024diagnosisandmanagement pages 1-2, girelli2024diagnosisandmanagement pages 2-4)
• Lucas MR et al. HFE genotypes, haemochromatosis diagnosis and clinical outcomes at age 80 years: a prospective cohort study in the UK Biobank. BMJ Open. Mar 2024. https://doi.org/10.1136/bmjopen-2023-081926 (lucas2024hfegenotypeshaemochromatosis pages 4-5)
• Marcon C et al. TSAT-Urated Insights: Clarifying the Complexities of Hereditary Hemochromatosis and Its Guidelines. Hemato. Dec 2024. https://doi.org/10.3390/hemato5040035 (marcon2024tsaturatedinsightsclarifying pages 16-17, marcon2024tsaturatedinsightsclarifying media 39ab28d3, marcon2024tsaturatedinsightsclarifying media 7ecf4a95, marcon2024tsaturatedinsightsclarifying media f71af5e5, marcon2024tsaturatedinsightsclarifying media 8a05bd9e, marcon2024tsaturatedinsightsclarifying pages 1-2)
• Delatycki MB, Allen KJ. Population Screening for Hereditary Haemochromatosis—Should It Be Carried Out, and If So, How? Genes. Jul 2024. https://doi.org/10.3390/genes15080967 (delatycki2024populationscreeningfor pages 1-2, delatycki2024populationscreeningfor pages 4-5)
• ClinicalTrials.gov. NCT04202965 (rusfertide/PTG‑300), results first posted 2023‑06‑15. https://clinicaltrials.gov/study/NCT04202965 (NCT04202965 chunk 1)
• ClinicalTrials.gov. NCT07332091 (vamifeport), record version 2026‑04‑30. https://clinicaltrials.gov/study/NCT07332091 (NCT07332091 chunk 4)

References

1. (girelli2024diagnosisandmanagement pages 1-2): Domenico Girelli, Giacomo Marchi, and Fabiana Busti. Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation. Hematology, 2024:434-442, Dec 2024. URL: https://doi.org/10.1182/hematology.2024000568, doi:10.1182/hematology.2024000568. This article has 22 citations and is from a peer-reviewed journal.

2. (girelli2024diagnosisandmanagement pages 2-4): Domenico Girelli, Giacomo Marchi, and Fabiana Busti. Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation. Hematology, 2024:434-442, Dec 2024. URL: https://doi.org/10.1182/hematology.2024000568, doi:10.1182/hematology.2024000568. This article has 22 citations and is from a peer-reviewed journal.

3. (szczerbinska2024hemochromatosis—hownotto pages 8-10): Agnieszka Szczerbinska, Beata Kasztelan-Szczerbinska, Anna Rycyk-Bojarzynska, Janusz Kocki, and Halina Cichoz-Lach. Hemochromatosis—how not to overlook and properly manage “iron people”—a review. Journal of Clinical Medicine, 13:3660, Jun 2024. URL: https://doi.org/10.3390/jcm13133660, doi:10.3390/jcm13133660. This article has 14 citations.

4. (szczerbinska2024hemochromatosis—hownotto pages 1-2): Agnieszka Szczerbinska, Beata Kasztelan-Szczerbinska, Anna Rycyk-Bojarzynska, Janusz Kocki, and Halina Cichoz-Lach. Hemochromatosis—how not to overlook and properly manage “iron people”—a review. Journal of Clinical Medicine, 13:3660, Jun 2024. URL: https://doi.org/10.3390/jcm13133660, doi:10.3390/jcm13133660. This article has 14 citations.

5. (lucas2024hfegenotypeshaemochromatosis pages 4-5): Mitchell R Lucas, Janice L Atkins, Luke C Pilling, Jeremy D Shearman, and David Melzer. Hfe genotypes, haemochromatosis diagnosis and clinical outcomes at age 80 years: a prospective cohort study in the uk biobank. BMJ Open, 14:e081926, Mar 2024. URL: https://doi.org/10.1136/bmjopen-2023-081926, doi:10.1136/bmjopen-2023-081926. This article has 42 citations and is from a peer-reviewed journal.

6. (NCT04202965 chunk 1): PTG-300 in Subjects With Hereditary Hemochromatosis. Protagonist Therapeutics, Inc.. 2020. ClinicalTrials.gov Identifier: NCT04202965

7. (szczerbinska2024hereditaryhemochromatosis–hownot pages 8-9): A Szczerbinska and B Kasztelan-Szczerbinska. Hereditary hemochromatosis–how not to overlook and properly manage “iron people”-a critical overview. Unknown journal, 2024.

8. (marcon2024tsaturatedinsightsclarifying pages 16-17): Chiara Marcon, Marta Medeot, Alessio Michelazzi, Valentina Simeon, Alessandra Poz, Sara Cmet, Elisabetta Fontanini, Anna Rosa Cussigh, Marianna Chiozzotto, and Giovanni Barillari. Tsat-urated insights: clarifying the complexities of hereditary hemochromatosis and its guidelines. Hemato, 5:459-489, Dec 2024. URL: https://doi.org/10.3390/hemato5040035, doi:10.3390/hemato5040035. This article has 2 citations.

9. (lucas2024hfegenotypeshaemochromatosis pages 7-7): Mitchell R Lucas, Janice L Atkins, Luke C Pilling, Jeremy D Shearman, and David Melzer. Hfe genotypes, haemochromatosis diagnosis and clinical outcomes at age 80 years: a prospective cohort study in the uk biobank. BMJ Open, 14:e081926, Mar 2024. URL: https://doi.org/10.1136/bmjopen-2023-081926, doi:10.1136/bmjopen-2023-081926. This article has 42 citations and is from a peer-reviewed journal.

10. (lucas2024hfegenotypeshaemochromatosis pages 6-7): Mitchell R Lucas, Janice L Atkins, Luke C Pilling, Jeremy D Shearman, and David Melzer. Hfe genotypes, haemochromatosis diagnosis and clinical outcomes at age 80 years: a prospective cohort study in the uk biobank. BMJ Open, 14:e081926, Mar 2024. URL: https://doi.org/10.1136/bmjopen-2023-081926, doi:10.1136/bmjopen-2023-081926. This article has 42 citations and is from a peer-reviewed journal.

11. (marcon2024tsaturatedinsightsclarifying pages 1-2): Chiara Marcon, Marta Medeot, Alessio Michelazzi, Valentina Simeon, Alessandra Poz, Sara Cmet, Elisabetta Fontanini, Anna Rosa Cussigh, Marianna Chiozzotto, and Giovanni Barillari. Tsat-urated insights: clarifying the complexities of hereditary hemochromatosis and its guidelines. Hemato, 5:459-489, Dec 2024. URL: https://doi.org/10.3390/hemato5040035, doi:10.3390/hemato5040035. This article has 2 citations.

12. (lucas2025geneticandlifestyle pages 12-15): Mitchell R Lucas, João Delgado, Robin N Beaumont, Gareth Hawkes, Andrew R Wood, Caroline F Wright, Jeremy Shearman, Janice L Atkins, and Luke C Pilling. Genetic and lifestyle modifiers of haemochromatosis-related clinical outcomes in hfe c282y homozygotes: prospective cohort study in uk biobank. MedRxiv, Aug 2025. URL: https://doi.org/10.1101/2025.08.22.25334187, doi:10.1101/2025.08.22.25334187. This article has 0 citations.

13. (marcon2024tsaturatedinsightsclarifying media 39ab28d3): Chiara Marcon, Marta Medeot, Alessio Michelazzi, Valentina Simeon, Alessandra Poz, Sara Cmet, Elisabetta Fontanini, Anna Rosa Cussigh, Marianna Chiozzotto, and Giovanni Barillari. Tsat-urated insights: clarifying the complexities of hereditary hemochromatosis and its guidelines. Hemato, 5:459-489, Dec 2024. URL: https://doi.org/10.3390/hemato5040035, doi:10.3390/hemato5040035. This article has 2 citations.

14. (marcon2024tsaturatedinsightsclarifying media 7ecf4a95): Chiara Marcon, Marta Medeot, Alessio Michelazzi, Valentina Simeon, Alessandra Poz, Sara Cmet, Elisabetta Fontanini, Anna Rosa Cussigh, Marianna Chiozzotto, and Giovanni Barillari. Tsat-urated insights: clarifying the complexities of hereditary hemochromatosis and its guidelines. Hemato, 5:459-489, Dec 2024. URL: https://doi.org/10.3390/hemato5040035, doi:10.3390/hemato5040035. This article has 2 citations.

15. (marcon2024tsaturatedinsightsclarifying media f71af5e5): Chiara Marcon, Marta Medeot, Alessio Michelazzi, Valentina Simeon, Alessandra Poz, Sara Cmet, Elisabetta Fontanini, Anna Rosa Cussigh, Marianna Chiozzotto, and Giovanni Barillari. Tsat-urated insights: clarifying the complexities of hereditary hemochromatosis and its guidelines. Hemato, 5:459-489, Dec 2024. URL: https://doi.org/10.3390/hemato5040035, doi:10.3390/hemato5040035. This article has 2 citations.

16. (marcon2024tsaturatedinsightsclarifying media 8a05bd9e): Chiara Marcon, Marta Medeot, Alessio Michelazzi, Valentina Simeon, Alessandra Poz, Sara Cmet, Elisabetta Fontanini, Anna Rosa Cussigh, Marianna Chiozzotto, and Giovanni Barillari. Tsat-urated insights: clarifying the complexities of hereditary hemochromatosis and its guidelines. Hemato, 5:459-489, Dec 2024. URL: https://doi.org/10.3390/hemato5040035, doi:10.3390/hemato5040035. This article has 2 citations.

17. (nogueyra2024thegeneticdiagnostics pages 3-4): Sol Villa Nogueyra, María F Trujillo Rodríguez, María L Garcia Oliva, Andrea Vidal-Gallardo, Amanda Ramírez Leal, Jose Beltran Hernandez, Andres Manuel Vargas Beltran, José D Guillen Sandoval, David Arriaga Escamilla, and Marily Martinez Ramirez. The genetic diagnostics of hemochromatosis: disparities in low- versus high-income countries. Cureus, Jul 2024. URL: https://doi.org/10.7759/cureus.64074, doi:10.7759/cureus.64074. This article has 3 citations.

18. (szczerbinska2024hereditaryhemochromatosis–hownot pages 9-11): A Szczerbinska and B Kasztelan-Szczerbinska. Hereditary hemochromatosis–how not to overlook and properly manage “iron people”-a critical overview. Unknown journal, 2024.

19. (marcon2024tsaturatedinsightsclarifying pages 31-31): Chiara Marcon, Marta Medeot, Alessio Michelazzi, Valentina Simeon, Alessandra Poz, Sara Cmet, Elisabetta Fontanini, Anna Rosa Cussigh, Marianna Chiozzotto, and Giovanni Barillari. Tsat-urated insights: clarifying the complexities of hereditary hemochromatosis and its guidelines. Hemato, 5:459-489, Dec 2024. URL: https://doi.org/10.3390/hemato5040035, doi:10.3390/hemato5040035. This article has 2 citations.

20. (NCT07332091 chunk 4): Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis. CSL Behring. 2026. ClinicalTrials.gov Identifier: NCT07332091

21. (delatycki2024populationscreeningfor pages 1-2): Martin B. Delatycki and Katrina J. Allen. Population screening for hereditary haemochromatosis—should it be carried out, and if so, how? Genes, 15:967, Jul 2024. URL: https://doi.org/10.3390/genes15080967, doi:10.3390/genes15080967. This article has 5 citations.

22. (delatycki2024populationscreeningfor pages 4-5): Martin B. Delatycki and Katrina J. Allen. Population screening for hereditary haemochromatosis—should it be carried out, and if so, how? Genes, 15:967, Jul 2024. URL: https://doi.org/10.3390/genes15080967, doi:10.3390/genes15080967. This article has 5 citations.

23. (delatycki2024populationscreeningfor pages 5-6): Martin B. Delatycki and Katrina J. Allen. Population screening for hereditary haemochromatosis—should it be carried out, and if so, how? Genes, 15:967, Jul 2024. URL: https://doi.org/10.3390/genes15080967, doi:10.3390/genes15080967. This article has 5 citations.

24. (szczerbinska2024hemochromatosis—hownotto pages 13-14): Agnieszka Szczerbinska, Beata Kasztelan-Szczerbinska, Anna Rycyk-Bojarzynska, Janusz Kocki, and Halina Cichoz-Lach. Hemochromatosis—how not to overlook and properly manage “iron people”—a review. Journal of Clinical Medicine, 13:3660, Jun 2024. URL: https://doi.org/10.3390/jcm13133660, doi:10.3390/jcm13133660. This article has 14 citations.